elagolix

Details:

Elagolix is an oral GnRH antagonist jointly developed by Abbvie and its partner Neurocrine Biosciences. By inhibiting the release of hormone receptors from the pituitary gland, elagolix ultimately reduces the level of circulating gonadal hormones. Currently, AbbVie is investigating the treatment of elagoli for some diseases mediated by sex hormones, such as uterine fibroids and endometriosis. So far, there have been more than 40 clinical trials of elagoli, involving more than 3000 patients. In addition, the phase III clinical trial of elagoli for the treatment of uterine fibroids is also underway, which has great market prospects. Olagoli chemical name: 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl) )Phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxa-1(2H)-pyrimidinyl]-1-phenethyl]amino]butanoic acid.

PCT patent WO2005007165A reports the synthesis method of oxagoli, using 2-fluoro-6-trifluoromethyl benzonitrile as a raw material, first reducing the cyano group with borane, and then condensing with urea under the action of hydrochloric acid to obtain 1-( 2-fluoro-6-trifluoromethyl phenethyl) urea intermediate, followed by cyclization reaction with dipolyvinyl ketone to obtain intermediate 1-[2-fluoro-6-(trifluoromethyl)benzyl]- 6-Methylpyrimidine-2,4(1H,3H)-dione, after bromination and amine alkylation, it undergoes Suzuki coupling reaction with 2-fluoro-3-methoxyphenylboronic acid and is removed by acid The Boc protecting group is used to obtain the key intermediate, which is finally reacted with 4-bromo-n-butyric acid through condensation and hydrolysis to obtain the final product.